Comparative clinical-functional effectiveness and cardiological safety of short-acting combined broncholytics in 2 months basic therapy in COPD patients

Y. Feschenko, L. Yashyna, M. Polianska, N. Kramarska (Kiev, Ukraine)

Source: Annual Congress 2007 - Treatment of COPD
Session: Treatment of COPD
Session type: Thematic Poster Session
Number: 589
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Y. Feschenko, L. Yashyna, M. Polianska, N. Kramarska (Kiev, Ukraine). Comparative clinical-functional effectiveness and cardiological safety of short-acting combined broncholytics in 2 months basic therapy in COPD patients. Eur Respir J 2007; 30: Suppl. 51, 589

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effectivenss and cardiological safety of short-acting combined broncholytics
Source: Eur Respir J 2006; 28: Suppl. 50, 53s
Year: 2006

Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006

Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Effectiveness of prolonged cholinolytic in complex basic therapy on the tolerability of physical load in severe bronchial asthma patients
Source: Annual Congress 2008 - Markers and triggers of asthma
Year: 2008

An evaluation of the safety, efficacy and cost-effectiveness for patients with acute respiratory illness, of a community-based intravenous medication service: The first 26 months
Source: Annual Congress 2011 - The impact of the organisation of care on costs: the role of the physician in home care
Year: 2011



Safety profile of tiotropium add-on therapy in paediatric patients by gender
Source: International Congress 2018 – Innovative therapies in asthma and COPD
Year: 2018



Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021


LABA/LAMA combinations efficacy evaluation therapy of COPD patients with emphasized morning and night symptoms
Source: International Congress 2018 – COPD management
Year: 2018

Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001

One-year pulmonary safety and efficacy of inhaled insulin as adjunctive therapy in type 2 diabetes patients poorly controlled on oral agent monotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 618s
Year: 2004

The clinico-immunological evaluation of the ribomunyl therapy in complex treatment of COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 674s
Year: 2006

Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

The effectiveness and safety of pre-hospital nebulizer therapy of elderly patients with bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 503s
Year: 2002

Long-term safety and efficacy of budesonide/formoterol in Japanese patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008

Efficacy of traditional and combined therapy in patients with sarcoidosis
Source: Eur Respir J 2003; 22: Suppl. 45, 234s
Year: 2003

Initial anticholinergic therapy COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 29s
Year: 2006

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities
Source: Eur Respir Rev, 26 (145) 160123; 10.1183/16000617.0123-2016
Year: 2017



Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013

Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 379s
Year: 2004